Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07132684 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

StatusRecruiting
PhasePhase 3
Started2025-08-31
View on ClinicalTrials.gov ↗

Amendment history

2026-02-26
Study Status, Oversight, Study Description, Arms and Interventions, Eligibility v2
Eligibility criteriarevised
Inclusion Criteria: Diagnosis of AML according to WHO (2022) or ICC criteria. Age ≥6055 and ≤75 years. ECOG performance status score of 0-2. Adequa [...]
2025-09-30
Not Yet Recruiting→Recruiting Study Status, Outcome Measures, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-08-30→confirmed 2025-08-31
Study sites0→1
2025-08-13
Original filing
This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.
Trial Details
NCT Number NCT07132684
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions AML, Adult
Enrollment 240 participants
Start Date 2025-08-31
Primary Completion 2027-08-30 (estimated)
Study Completion 2028-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-02